Page 5 - Upstream Processing News Today

Construction of Samsung Biologics’ new facility is on track, with the CDMO saying pre-sales activities are ongoing for Plant 4, as it is known, despite the challenging business environment amid the COVID-19 pandemic.

Biotecnica has launched a new line of low endotoxin peptones that do not require ultrafiltration.

Rentschler Biopharma and XL-protein have teamed up on the manufacture of what they say is a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I) that may open better treatment options for patients suffering from inflammation, chronic or autoimmune diseases.

Merck has launched new technology and is set to expand manufacturing capacity to advance antibody-drug conjugates (ADC) therapies.

From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.

Merck KGgA and subsidiary MilliporeSigma have completed work on their second Carlsbad, California-based facility.

LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.

Avid Bioservices, Inc. is expanding its CDMO service offering into the cell and gene therapy market: constructing a purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.

Measuring total LNG supply chain methane emissions is imprecise, but there is an even bigger data gap when it comes to coal. Without accurate measurement, the benefits of coal-to-LNG switching risk being under-appreciated. [Gas in Transition, Volume 1, Issue 6]

PTC Therapeutics is celebrating the opening of a new gene therapy manufacturing facility in Hopewell, N.J.